N-Power Medicine receives Series B funding

N-Power Medicinea clinical trials company based in Redwood City, California, has raised an undisclosed amount in its second round of financing.

The round, which totaled $72 million, was led by the Merck Global Health Innovation Fund, with participation from a US-based healthcare-focused investor.

N-Power Medicine is also collaborating with Merck (known as MSD outside the United States and Canada) to enable a greater number of oncologists and the patients they care for to participate in clinical research.

The company intends to use the funds to expand its network of oncology clinics and collaborations with biopharmaceutical companies, leveraging its platform to integrate clinical research into everyday patient care.

Founded in 2021 and led by CEO Mark Lee, N-Power Medicine aims to accelerate the drug development process and provide patients with faster access to innovative therapies. The company has developed an integrated platform that provides a unified workflow for both clinical trials and routine patient care. N-Power’s “Human in the Loop” model, consisting of virtual and on-site staff supported by AI-powered workflow automation, helps oncologists generate research-ready data for all patients in the practice and create standardized clinical documentation for the medical record.

The platform consists of three basic components:

• The Kaleido™ Registry, which collects prospective, standardized, real-time patient data specifically designed to support clinical trials and drug development. To date, over 7,000 patients have consented and enrolled in the registry.
• Point-of-care technology enables seamless workflow management, provides access to patient data and insights, while ensuring compliance with regulatory requirements and quality standards for prospective clinical research.
• Onsite and virtual experts support oncologists and research staff in operationalizing the registry and clinical documentation while reducing their overall workload so they can focus on patient care and research.

Because all patients participate in the registry, standardized data collection enables easily actionable insights for clinical research, such as proactive, real-time identification of study-eligible patients and patient characteristics and outcomes that inform study design.

FinSMEs

01.07.2024